Valsartan 320 mg Tablets, HDPE 90 cc bottles in cardboard trays, Rx Only, RemedyRepack, Inc., 625...
FDA Drug Recall #D-1102-2018 — Class II — August 10, 2018
Recall Summary
| Recall Number | D-1102-2018 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 10, 2018 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | RemedyRepack Inc. |
| Location | Indiana, PA |
| Product Type | Drugs |
| Quantity | 36 bottles of 90 = 3240 tablets |
Product Description
Valsartan 320 mg Tablets, HDPE 90 cc bottles in cardboard trays, Rx Only, RemedyRepack, Inc., 625 Kolter Drive, Suite 4, Indiana, PA 15701, NDC 61786-0793-19
Reason for Recall
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Distribution Pattern
Product was distributed to three customers in FL and VA.
Lot / Code Information
Lot # B0362988-110917, exp. date 10/2018 Lot # B0432265-050318, exp. date 05/2019 Lot # B0450321-061218, exp. date 06/2019 Lot # B0450322-061218, exp. date 05/2019 Lot # B0408652-030718, exp. date 02/2019
Other Recalls from RemedyRepack Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0411-2025 | Class II | Clindamycin HCl Capsule, 300 mg, QTY: 30 Capsul... | Apr 22, 2025 |
| D-0378-2025 | Class II | Clindamycin HCl, 300 mg Capsule, QTY: 30 Capsul... | Mar 24, 2025 |
| D-0217-2025 | Class II | Carvedilol 25 mg Tablet, QTY: 30 Tablets per Bl... | Jan 24, 2025 |
| D-0165-2025 | Class II | Duloxetine Delayed-Release Capsules, 60 mg, a) ... | Dec 2, 2024 |
| D-0611-2024 | Class II | Potassium Chloride Micro 10mEq K (750 mg) Exten... | Jun 26, 2024 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.